Rongchang Bioscience (09995.HK) announced its interim results, with a net loss of about 450 million yuan, a decrease of 42.4% year-on-year.

Wisdom Financial News APP News, Rongchang Bio (09995.HK) announced its mid-term performance in 2025, with revenue from product sales and R&D services reaching 1.092 billion yuan, a year-on-year increase of 47.6%; R&D expenses decreased by 19.7% year-on-year to 647 million yuan, with a net loss of approximately 450 million yuan, a year-on-year decrease of 42.4%; loss per share was 0.83 yuan.